US President Donald Trump stated that he had asked French President Emmanuel Macron to raise the prices of French prescription drugs by two to three times, threatening to impose a 100% tariff on French wine and champagne entering the US if Macron did not comply. He also mentioned that Macron subsequently agreed and requested not to impose the tariff, using the same argument with about ten other countries.

The French presidency previously dismissed similar statements as fake news: the president does not set drug prices, which are regulated by the social security system and remain stable, as anyone who has visited a French pharmacy knows. Trump's public recounting of the conversation also included a 25% general tariff and "three minutes of negotiation among three countries." In June 2026, he linked the 100% wine tax to the French digital services tax in an interview with the New York Post, to which Macron responded that tariffs are unhelpful, the digital tax is European legislation, and there are existing tariff arrangements between the US and Europe. At that time, EU exports of alcoholic beverages to the US faced about a 15% tariff, with France lobbying to reduce it to zero. There was no official drug price index published that contradicted the presidency's statement regarding any potential price increase.

Verbal agreements are not the same as signed drug pricing laws. The threat of wine tariffs has appeared multiple times, switching between drug prices and digital taxes as the linked subjects. The list of ten countries was not named individually in this statement.

Wine serves as a visible export hostage to the US. The pricing authority for healthcare is with the social security committee, not solely at the Élysée Palace.

In market mechanics, the buyer is the White House, aiming to raise overseas drug prices to alter relative prices in the US, while the sellers are French wine merchants and the European drug pricing system. The driving force is the president's verbal threats, which constitute trade threats. Funds have not automatically redirected due to this statement. The beneficiaries are the narrative of US pharmaceutical pricing, while the pressured parties are French wineries with high exposure to the US market and the EU's unified tariffs involved in the bilateral verbal agreements.

Source: Public Information